Monopar Therapeutics, Inc. (MNPR)
|Net Income (ttm)||-5.38M|
|Trading Day||January 27|
|Day's Range||6.51 - 6.72|
|52-Week Range||4.36 - 19.50|
Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs
-Issued patent expands and strengthens Monopar's existing camsirubicin IP portfolio -Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase p...
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM
Validive ® Phase 2b/3 Clinical Trial on Track to Start Before Year-end Issuance of New Patents For Validive Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®
Strengthens Monopar's Validive IP Portfolio To 2035 Strengthens Monopar's Validive IP Portfolio To 2035
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate u...
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly develop...
Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis. and MORGAN HILL, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (B...
Due to the disjointed fundamentals, many investors were caught off guard with this current bull market. However, there are cheap stocks to buy that are still available.
With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy to capitalize on this trend.
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
Potential Companion Diagnostic to Monopar’s uPRIT Program Potential Companion Diagnostic to Monopar’s uPRIT Program
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloi...
Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Technology Collaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Tec...
Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR
CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that ...
Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher on Tuesday, after the company announced it joined forces with NorthStar to develop a radio-immuno-therapeutics to target severe co...
Monopar Therapeutics, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal a... [Read more...]
|IPO Date |
Dec 19, 2019
Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc
|Stock Exchange |
|Ticker Symbol |
According to 2 analysts, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is 30.33, which is an increase of 359.55% from the latest price.